[go: up one dir, main page]

WO2001005425A3 - Combined preparations comprising daunorubicin derivatives and her2 antibodies - Google Patents

Combined preparations comprising daunorubicin derivatives and her2 antibodies Download PDF

Info

Publication number
WO2001005425A3
WO2001005425A3 PCT/EP2000/006540 EP0006540W WO0105425A3 WO 2001005425 A3 WO2001005425 A3 WO 2001005425A3 EP 0006540 W EP0006540 W EP 0006540W WO 0105425 A3 WO0105425 A3 WO 0105425A3
Authority
WO
WIPO (PCT)
Prior art keywords
her2 antibodies
combined preparations
daunorubicin
daunorubicin derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/006540
Other languages
French (fr)
Other versions
WO2001005425A2 (en
Inventor
Cristina Geroni
Marina Ripamonti
Michele Caruso
Antonino Suarato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Priority to JP2001510479A priority Critical patent/JP2003504413A/en
Priority to AU59839/00A priority patent/AU5983900A/en
Priority to EP00945903A priority patent/EP1200098A2/en
Publication of WO2001005425A2 publication Critical patent/WO2001005425A2/en
Publication of WO2001005425A3 publication Critical patent/WO2001005425A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There are provided the combined use of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4'-methansulfonyl daunorubicin and a recombinant humanized anti-HER2 antibody, preferably trastuzumab, in the treatment of tumors and the use of said combination in the treatment and/or prevention of tumor metastasis.
PCT/EP2000/006540 1999-07-20 2000-07-10 Combined preparations comprising daunorubicin derivatives and her2 antibodies Ceased WO2001005425A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001510479A JP2003504413A (en) 1999-07-20 2000-07-10 Combination preparation containing an antitumor substance
AU59839/00A AU5983900A (en) 1999-07-20 2000-07-10 Combined preparations comprising antitumor agents
EP00945903A EP1200098A2 (en) 1999-07-20 2000-07-10 Combined preparations comprising daunorubicin derivatives and anti her2 antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9917012.8 1999-07-20
GBGB9917012.8A GB9917012D0 (en) 1999-07-20 1999-07-20 Combined preparations comprising antitumor agents

Publications (2)

Publication Number Publication Date
WO2001005425A2 WO2001005425A2 (en) 2001-01-25
WO2001005425A3 true WO2001005425A3 (en) 2001-05-17

Family

ID=10857596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006540 Ceased WO2001005425A2 (en) 1999-07-20 2000-07-10 Combined preparations comprising daunorubicin derivatives and her2 antibodies

Country Status (5)

Country Link
EP (1) EP1200098A2 (en)
JP (1) JP2003504413A (en)
AU (1) AU5983900A (en)
GB (1) GB9917012D0 (en)
WO (1) WO2001005425A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282443B1 (en) 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
GB0114654D0 (en) * 2001-06-15 2001-08-08 Pharmacia & Upjohn Spa Anti-tumor compound
UA94899C2 (en) 2005-01-21 2011-06-25 Дженентек, Инк. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
EP2132573B1 (en) 2007-03-02 2014-04-23 Genentech, Inc. Predicting response to a her dimerisation inhbitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
DK2171090T3 (en) 2007-06-08 2013-06-10 Genentech Inc Gene expression markers for tumor resistance to HER2 inhibitor therapy
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
ES2572728T3 (en) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Bispecific anti-HER antibodies
CA2761280A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
CN102892779B (en) 2010-02-18 2016-12-21 基因泰克公司 Neuregulin antagonist and the purposes in treatment cancer thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
MX2014001766A (en) 2011-08-17 2014-05-01 Genentech Inc Neuregulin antibodies and uses thereof.
CN106987620A (en) 2011-11-30 2017-07-28 霍夫曼-拉罗奇有限公司 Erbb3 mutation in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (en) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Diagnosis and treatment of HER3 inhibitors
WO2014083178A1 (en) 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Identification of patients in need of pd-l1 inhibitor cotherapy
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
US10167342B2 (en) 2016-08-29 2019-01-01 Fazel Shokri Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
PT110526B (en) 2018-01-26 2021-02-04 Univ Nova De Lisboa ANTIBODY, FUNCTIONAL FRAGMENT OR PROBE OF THE SAME AGAINST TUMORAL ANTIGENS
IL300314A (en) 2020-10-08 2023-04-01 Affimed Gmbh Trispecific binders
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
EP4426439A1 (en) 2021-11-03 2024-09-11 Affimed GmbH Bispecific cd16a binders
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0328147A2 (en) * 1988-02-11 1989-08-16 Bristol-Myers Squibb Company Anthracycline immunoconjugates having a novel linker and methods for their production
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
WO1999031140A1 (en) * 1997-12-12 1999-06-24 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2000044225A1 (en) * 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu
WO2000061185A1 (en) * 1999-04-09 2000-10-19 Aventis Pharma S.A Docetaxel in combination with rhumab her2 for the treatment of cancers
WO2000069460A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5677171A (en) * 1988-01-12 1997-10-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
EP0328147A2 (en) * 1988-02-11 1989-08-16 Bristol-Myers Squibb Company Anthracycline immunoconjugates having a novel linker and methods for their production
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
WO1999031140A1 (en) * 1997-12-12 1999-06-24 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2000044225A1 (en) * 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu
WO2000061185A1 (en) * 1999-04-09 2000-10-19 Aventis Pharma S.A Docetaxel in combination with rhumab her2 for the treatment of cancers
WO2000069460A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BASELGA J ET AL: "HER2 Overexpression and Paclitaxel sensitivity in breast cancer: Therapeutic implications", ONCOLOGY,CH,S. KARGER AG, BASEL, vol. 11, no. 3, SUPPL. 02, March 1997 (1997-03-01), pages 43 - 48, XP002100077, ISSN: 0030-2414 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US7498030B2 (en) 1999-06-25 2009-03-03 Genetech, Inc. Treatment with anti-ErbB2 antibodies and anti-hormonal compounds
US7501122B2 (en) 1999-06-25 2009-03-10 Genentech, Inc. Treatment with anti-ErbB2 antibody combinations
US7618631B2 (en) 1999-06-25 2009-11-17 Genentech, Inc. Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells

Also Published As

Publication number Publication date
AU5983900A (en) 2001-02-05
WO2001005425A2 (en) 2001-01-25
JP2003504413A (en) 2003-02-04
EP1200098A2 (en) 2002-05-02
GB9917012D0 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
WO2001005425A3 (en) Combined preparations comprising daunorubicin derivatives and her2 antibodies
AU5365296A (en) Human monoclonal antibody against lung carcinoma
WO1997019111A3 (en) Monoclonal antibodies anti-cd6 and their uses
CA2249320A1 (en) Glycosylated humanized b-cell specific antibodies
ZA200110263B (en) Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies.
DK0586002T3 (en) Monoclonal antibodies that recognize the epidermal growth factor receptor, its cells and methods, and preparations thereof
AU1462300A (en) Human pan-hcv human monoclonal antibodies
CA2072249A1 (en) Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
IL214084A (en) Kit comprising humanized anti-erbb2 antibodies and instructions for their use to treat breast cancer
AU1704099A (en) Monoclonal human natural antibodies
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
AU5047800A (en) Breast, gastric and prostate cancer associated antigens and uses therefor
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU2407899A (en) Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU5441000A (en) Human monoclonal antibody
HUP9800613A3 (en) Humanized antibody against human fas-antigene
AU2003215381A1 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
ZA941645B (en) Antibodies specifically reactive against human prostate specific antigen.
AU1809695A (en) Tumor associated monoclonal antibody 123av16
AU6227800A (en) Recombinant antibody directed against human sperm antigen
AU2002326318A1 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000945903

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000945903

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000945903

Country of ref document: EP